Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA.
Department of Immunology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Sci Rep. 2017 Jan 3;7:39751. doi: 10.1038/srep39751.
Regulatory T-cells (Tregs) play a pivotal role in maintaining peripheral tolerance. Increasing Treg numbers/functions has been shown to ameliorate autoimmune diseases. However, common Treg expansion approaches use T-Cell Receptor (TCR)-mediated stimulation which also causes proliferation of effector T-cells (Teff). To overcome this limitation, purified patient-specific Tregs are expanded ex vivo and transfused. Although promising, this approach is not suitable for routine clinical use. Therefore, an alternative approach to selectively expand functional Tregs in vivo is highly desired. We report a novel TCR-independent strategy for the selective proliferation of Foxp3+Tregs (without Teff proliferation), by co-culturing CD4+ T-cells with OX40 L+Jagged(JAG)-1+ bone marrow-derived DCs differentiated with GM-CSF or treating them with soluble OX40 L and JAG1 in the presence of exogenous IL-2. Tregs expanded using soluble OX40 L and JAG1 were of suppressive phenotype and delayed the onset of diabetes in NOD mice. Ligation of OX40 L and JAG1 with their cognate-receptors OX40 and Notch3, preferentially expressed on Tregs but not on Teff cells, was required for selective Treg proliferation. Soluble OX40L-JAG1-induced NF-κB activation as well as IL-2-induced STAT5 activation were essential for the proliferation of Tregs with sustained Foxp3 expression. Altogether, these findings demonstrate the utility of soluble OX40 L and JAG1 to induce TCR-independent Treg proliferation.
调节性 T 细胞(Tregs)在维持外周耐受中发挥着关键作用。增加 Treg 的数量/功能已被证明可以改善自身免疫性疾病。然而,常见的 Treg 扩增方法使用 T 细胞受体(TCR)介导的刺激,这也会导致效应 T 细胞(Teff)的增殖。为了克服这一限制,纯化的患者特异性 Tregs 在体外扩增并输注。尽管有前景,但这种方法不适合常规临床使用。因此,高度需要一种替代方法来选择性地在体内扩增功能性 Tregs。我们报告了一种新型的 TCR 非依赖性策略,通过共培养 CD4+T 细胞与 OX40L+Jagged(JAG)-1+GM-CSF 分化的骨髓来源的树突状细胞,或在存在外源性 IL-2 的情况下用可溶性 OX40L 和 JAG1 处理它们,来选择性地扩增 Foxp3+Tregs(不扩增 Teff)。使用可溶性 OX40L 和 JAG1 扩增的 Tregs 具有抑制表型,并延迟 NOD 小鼠糖尿病的发病。OX40L 和 JAG1 与其同源受体 OX40 和 Notch3 的结合,优先表达在 Tregs 上而不是 Teff 细胞上,这是 Treg 选择性增殖所必需的。可溶性 OX40L-JAG1 诱导的 NF-κB 激活以及 IL-2 诱导的 STAT5 激活对于维持 Foxp3 表达的 Treg 的增殖是必需的。总之,这些发现证明了可溶性 OX40L 和 JAG1 诱导 TCR 非依赖性 Treg 增殖的效用。